Building synthetic lethality from concept into reality at GSK
CRISPR-based tools have revolutionized the discovery of several synthetically lethal combinations that are currently in clinical trials. This progress demonstrates the potential of CRISPR technology to dramatically alter cancer target discovery and create a wave of new therapeutics over the next decade.,
At GSK, our industry-leading synthetic lethality research unit is working to advance our preclinical program capacity while further understanding the underlying mechanisms of synthetic lethality drug resistance. Our larger vision in R&D is to identify novel targets in drug-resistant patient populations, underpinning our goal to deliver potentially transformational medicines in oncology.
In June of 2020, GSK and IDEAYA Biosciences formed a strategic partnership to advance three novel synthetic lethality assets, including as monotherapy and as combinations between GSK and IDEAYA programs. This partnership enables compelling potential combinations and the opportunity to build an industry leading pipeline that targets molecularly defined populations in several major solid tumors. The collaboration has the potential to bring the next generation of innovative precision medicine therapies to patients utilizing the approach of synthetic lethality, and could have meaningful impact for the clinical care of patients with lung, prostate, breast, colorectal and ovarian cancers.
 Bridges, C. The origin of variations in sexual and sex-limited characters. Am. Nat. 1922;56(642):51-63.
 Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-21.
 Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017;355(6330):1152-8.
 Huang A, Garraway LA, Ashworth A, et al. Synthetic lethality as an engine for cancer drug target discovery. Nat. Rev. Drug Discov. 2019;11:1-6.
 > Behan FM, Iorio F, Picco G, et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. Nature. 2019;568(7753):511-6.
 Kaelin WG. Choosing anticancer drug targets in the postgenomic era. J Clin Invest. 1999;104(11):1503-6.
 Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer. 2005;5(9):689-98.
 Hartwell LH, Szankasi P, Roberts CJ, et al. Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997;278(5340):1064-8.
 Jariyal H, Weinberg F, Achreja A, et al. Synthetic lethality: a step forward for personalized medicine in cancer. Drug Discov. Today. 2020;25(2):305-20.